Wellington Biomedical Innovation Master Investors (Cayman) I L.P. - Jun 21, 2021 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
10%+ Owner
Signature
/s/ Wellington Biomedical Innovation Master Investors (Cayman) I L.P., By: Wellington Management Company LLP, as Investment Adviser, /s/ Peter McIsaac, Title: Authorized Person
Stock symbol
VERV
Transactions as of
Jun 21, 2021
Transactions value $
$0
Form type
4
Date filed
6/22/2021, 05:14 PM
Previous filing
Jun 16, 2021
Next filing
Jul 28, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERV Common Stock Conversion of derivative security +1.34M 1.34M Jun 21, 2021 Direct F1
transaction VERV Common Stock Conversion of derivative security +1.15M +85.81% 2.5M Jun 21, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Series A-2 Preferred Stock Conversion of derivative security -12.4M -100% 0 Jun 21, 2021 Common Stock 1.34M Direct F1
transaction VERV Series B Preferred Stock Conversion of derivative security -10.7M -100% 0 Jun 21, 2021 Common Stock 1.15M Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Wellington Biomedical Innovation Master Investors (Cayman) I L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date.
F2 The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.